Active pharmaceutical ingredients

Product Description

Parameters

Scan the QR code to read on your phone

the Recombinant SARS-COV-2 Fusion Protein Vaccine LIKANG V-01

None

Retail price

0.0

元

Market price

0.0

元

Number of views:

1000

Product serial number

相关产品

the Recombinant SARS-COV-2 Fusion Protein Vaccine LIKANG V-01

In September 2022, the Recombinant SARS-COV-2 Fusion Protein Vaccine LIKANG V-01 developed by Livzon Mabpharm Inc. in collaboration with the Institute of Biophysics, Chinese Academy of Sciences, was proposed by the National Health Commission and approved by the National Medical Products Administration upon demonstration to be included for the emergency use as sequential booster immunization.

Active pharmaceutical ingredients

Diagnostic Kit for IgM / IgG Antibody to Coronavirus (SARS-CoV-2) (Lateral Flow)

在线留言

Username used for comment:

不良报告

Description:

* Adverse events：

Name：

Area：

Phone：